Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a user whose insurance switched their prescription from finasteride to dutasteride, and they are considering whether to appeal the decision or continue with dutasteride. Other users suggest that both medications are affordable without insurance and that dutasteride may be more effective long-term.

The conversation is about the availability of the PP405 formula for hair loss treatment, with mentions of finasteride and its side effects. Users discuss the potential of obtaining the formula through unofficial channels and the challenges related to its genetic sequence and delivery method.

The conversation discusses using a dermapen for microneedling to treat hair loss, with specific mention of using Minoxidil, Finasteride, Dutasteride, RU58841, KX-826, and other topicals. The user experienced side effects like palpitations and itching after microneedling and applying these treatments.

The conversation discusses using both oral and topical finasteride, along with minoxidil, for hair loss treatment. The user reports progress with finasteride and considers switching to dutasteride for potentially better results.

The conversation discusses a user's unconventional hair loss treatment involving scalp massage, dermastamping, and pouring hot water to induce a burning sensation, with a warning not to try it without further evidence. Other users suggest more traditional treatments like Minoxidil and finasteride, while expressing skepticism and concern about the hot water method.

The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

The conversation discusses a hair loss treatment regimen involving 1mg finasteride every other day, 5% minoxidil twice daily, and a fin/minoxidil mix on non-pill days. The user is considering whether to continue this regimen or switch to daily finasteride or try other treatments like dutasteride.

The conversation is about a person experiencing hair loss from steroid use, considering treatments like RU58841, dutasteride, and Nizoral, while avoiding finasteride and Minoxidil due to concerns about hormones and hypertension. The consensus suggests using dutasteride or finasteride, as Nizoral alone is not effective.

The conversation is about hair loss treatments, specifically discussing the effectiveness of shampoos with Minoxidil and DHT-blocking properties. Users suggest using Minoxidil, tretinoin, and microneedling for hair regrowth, while recommending ketoconazole shampoo for scalp health.

The conversation discusses the application frequency of a 1% Koshine solution for hair loss, with recommendations varying between once or twice daily. It is noted that the 1% solution is more effective than the 0.5% solution.

The conversation discusses the frustration of having excessive body hair while experiencing scalp hair loss, with mentions of treatments like finasteride, minoxidil, and hair transplants using body hair. Users share experiences and advice, noting the role of genetics and DHT in hair growth patterns.

The conversation discusses hair loss treatments, specifically the use of 5% topical minoxidil, with considerations for adding finasteride or dutasteride. Concerns about side effects, such as unwanted body hair growth from oral minoxidil, are also mentioned.

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, RU58841, microneedling, ketoconazole shampoo, and laser therapy. Users emphasize the importance of consistency, patience, and individual response to treatments.

The conversation is about a user who experienced significant hair recovery using 5% Minoxidil and 0.1% Finasteride, specifically with the Traya brand. The user emphasizes consistency and early treatment for effective results, noting improvements in hair volume and some side effects like dry scalp.

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

The conversation discusses the application frequency of Koshine 1% for hair loss, with conflicting instructions between Amazon and the main website. The user is unsure whether to apply it once or twice daily.

The conversation discusses two hair loss treatments: Minoxidil 5% with Azelaic Acid 1.5% and Dutasteride 0.05% topical foam, and Finasteride 0.1% with Minoxidil 5% topical foam. Users express uncertainty about the effectiveness of topical Dutasteride, while topical Finasteride is generally considered effective.

The conversation is about a user who has been using topical minoxidil for 3 months and oral finasteride for 2.5 years to combat hair loss, with positive results so far. The user is curious about future hair growth and considers additional treatments like dermarolling and low-level laser therapy.

The conversation is about a user making a homemade topical dutasteride solution to use alongside testosterone replacement therapy (TRT) and oral dutasteride. The user aims to reduce DHT locally at the testosterone injection site and on the scalp.

The conversation is about the best concentration of Tretinoin to use with Minoxidil for hair growth, with suggestions ranging from 0.025% to 0.05%. Users discuss personal experiences and plans to adjust Tretinoin concentration for better results.

The conversation is about using tretinoin to enhance the effects of minoxidil for hair loss, with suggestions to switch from finasteride to dutasteride or use RU58841 for better results. Concerns about tretinoin causing dry scalp and its potential impact on hair loss progression are also discussed.

The conversation discusses the effectiveness and authenticity of RU58841 purchased from Amazon, with some users suggesting buying from reputable sources like Anagen Inc. Others recommend using oral finasteride instead of RU58841 due to concerns about product legitimacy.

The conversation is about using Bimatoprost for hair growth, with concerns about potential side effects like eye color change and fat atrophy. Users discuss combining it with other treatments like Minoxidil and Finasteride, and sourcing Bimatoprost in bulk.

The conversation discusses the use of topical finasteride for hair loss, with the user considering whether oral finasteride might be more effective in reducing DHT levels. Other users suggest alternatives like dutasteride, RU58841, saw palmetto, and a combination of Redensyl, Procapil, and Capixyl, while debating the effectiveness and side effects of these treatments.

The conversation discusses concerns about the effectiveness of finasteride for hair loss. The user is worried about being a non-responder to the treatment.

The conversation discusses hair regrowth progress using finasteride, minoxidil, and vitamin D, with some users experiencing shedding and others seeing improvement. Additional treatments like dutasteride, topical solutions, and lifestyle changes are also mentioned.

The conversation is about a user who has been using finasteride for 2.4 years to stop hair loss and is considering adding minoxidil for regrowth. Many users suggest adding minoxidil to improve hair regrowth, while some discuss the cost and effectiveness of treatments.

The conversation discusses treatments for Androgenetic Alopecia, including Minoxidil, finasteride, RU58841, and topical caffeine. It emphasizes that there are multiple treatment options available in 2025.